OBJECTIVE: To characterize the adaptations of lipid metabolism, with special emphasis on tissue lipoprotein lipase, to negative energy balance brought by chronic treatment of obese obaob mice with leptin. DESIGN: According to a 2 Â 2 factorial analysis, lean and obese C57BLa6J mice were subcutaneously infused with leptin (100 mg?kg 71 ?day 71 ) or vehicle (phosphate-buffered saline) during seven days. RESULTS: Cumulative food intake and ®nal body weight of vehicle-infused obese mice were twofold higher than in lean controls. Leptin decreased cumulative food intake and body weight of obese, but not lean mice. Lipoprotein lipase (LPL) activity in white inguinal and epididymal and brown interscapular adipose tissues of control obese mice was at least twofold higher than in lean mice, but comparable in the vastus lateralis muscle. Leptin treatment of obese mice signi®cantly lowered LPL activity to that of lean mice in all tissues examined. Vehicle-infused obese mice had higher liver triglyceride content and were hypertriglyceridemic compared to lean mice, and triglyceride concentrations in plasma and liver were decreased proportionally after leptin treatment. Leptin lowered glycemia and insulinemia of obese mice to lean levels and decreased plasma corticosterone. Leptin infusion had no notable effect on tissue lipoprotein lipase nor plasma variables of lean mice. CONCLUSIONS: Leptin infusion abolished hyperinsulinemia in the obaob mouse, an effect that was probably responsible for the concomitant normalization of adipose LPL activity. This study shows that decreased LPL activity, plasma triglyceride concentrations and hepatic triglyceride production constitute some of the adaptive peripheral adaptations of lipid metabolism, which accompany the reduction in fat mass accretion brought by leptin treatment of the obese obaob mouse.
Introduction
Leptin, the adipocyte-derived hormone encoded by the ob gene, is currently considered an important player in the regulation of energy balance (for reviews, see Refs 1±3 ). This hormone, whose rate of secretion is dictated by the size of fat mass, acts in the brain to reduce food intake 4, 5 and increase thermogenesis. 6, 7 Leptin primarily affects adipose tissue, promotes fat oxidation and catabolism, 8 ± 10 and sometimes leads to complete depletion of visible white adipose tissue when administered at high dose. 11 Most studies on the effects of leptin on energy balance have been focused on global variables, such as food intake, fat mass and thermogenesis. However, the metabolic adaptations, especially those of lipid metabolism, which must take place at the periphery to accommodate leptin-induced alterations in energy balance remain to be fully characterized.
Lipoprotein lipase (LPL; EC 3.1.1.34) constitutes a particularly important enzyme in lipid deposition and metabolism. At the luminal surface of capillary endothelial cells, LPL hydrolyzes the triglyceride (TG) component of circulating lipoprotein particles, allowing delivery of their constituent fatty acids to tissues (for reviews, see refs 12,13) . Generally, adipose tissue LPL activity is positively associated with fat mass accretion and obesity, 14 which underlines its key role in the peripheral adaptations to positive energy balance. Although there is at present no evidence for a direct action of leptin on LPL, the enzyme is affected by several hormones. Speci®cally, insulin and glucocorticoids constitute two major modulators of adipose LPL and peripheral lipid metabolism, and these hormones are particularly sensitive to energy¯ux. Since most studies have directly 15 or indirectly 7 reported leptin-induced alterations in insulin levels and action, LPL activity is likely to be modi®ed accordingly.
The aim of the study was therefore to assess the effects of chronic treatment of obese obaob mice with murine leptin on lipid metabolism, with special emphasis on adipose and muscle lipoprotein lipase. Liver TG content and plasma TG concentration were also assessed as indices of hepatic TG production and plasma TG transport, respectively, as were the LPL modulators, insulin and corticosterone.
Materials and methods

Animals and treatments
Ten lean Oba? and ten obese obaob male C57BLa6J mice (Jackson Laboratories, Bar Harbor, MN), initially aged 6±7 weeks, were housed individually in plastic cages with wood shavings, under controlled temperature (25 AE 1 C) and lighting (lights on between 07.00± 19.00 h), and had ad libitum access to food (4.5% fat, 14.4 kJag, pelleted stock diet, Charles River Rodent Animal Diet, distributed by Ralston Products, Woodstock, Canada) and tap water. All mice were cared for and handled in conformance with the Canadian Guide for the Care and Use of Laboratory Animals. After one week, an osmotic minipump (Alza Corporation, Palo Alto, CA), which had a¯ow rate of 0.5 mlah, was implanted s.c. in all mice under iso¯urane anesthesia. According to a 2 Â 2 factor design, the pump delivered phosphate-buffered saline (PBS; 136.75 mmolaL NaCl, 2.68 mmolaL KCl, 10.14 mmolaL Na 2 HPO 4 , 1.76 mmolaL KH 2 PO 4 , pH 7.4) in half of the lean and obese mice, and in the other half, a solution of murine leptin (kindly provided by Dr Frank Collins, Amgen Inc., Thousand Oaks, CA) dissolved in PBS at a concentration of 100 mgakg body weight per day for seven days. Food intake and body weight were recorded daily between 08.00±09.00 h during the treatment. Food was removed 24 h before killing, in order to avoid the strong acute effects on lipid metabolism of the nutritional status, which would have differed between PBS-and leptin-treated mice. In order to compare plasma variables under the habitual nutritional condition of the chronic treatment, an additional cohort of 10 lean and 10 obese male mice, treated identically as above but fed ad libitum until the end of the experiment, was used to determine the effects of leptin on plasma glucose, insulin and TG concentrations after normal ad libitum night access to food. Tissues were not available in this case for lipoprotein lipase (LPL) measurements. The data pertaining to this cohort are identi®ed as`postprandial'. On the day of the experiment, mice were anesthetized with an i.p. injection of 0.3±0.5 ml of a ketamine (40 mgaml): xylazine (2 mgaml) solution, and blood and tissues were extracted immediately thereafter.
Plasma and tissue sampling
Immediately following the opening of the thoracic cage, blood was collected by cardiac puncture, centrifuged (1500 g, for 15 min at 4 C), and the separated plasma was stored at 7 70 C until later biochemical measurements. A piece of liver was also removed, quickly frozen on dry ice and stored at 7 70 C. Epididymal (EWAT) and inguinal (IWAT) white adipose tissues, interscapular brown adipose tissue (BAT) and vastus lateralis muscle (VLM) were excised, and approximately 50 mg from each tissue was homogenized with all-glass tissue grinders (Kontes, Vineland, NJ). Adipose tissue samples were homogenized in 1 ml of a solution containing 0.25 molal sucrose, 1 mmolal ethylenediamine-tetraacetic acid (EDTA), 10 mmolal Tris-HCl and 12 mmolal deoxycholate, pH 7.4. Muscle samples were homogenized in 1 ml of a solution containing 1 molal ethylene glycol, 50 mmolal Tris-HCl, 3 mmolal deoxycholate, 10 IUaml heparin and 5% (vav) aprotinin (Trasylol, Miles Pharmaceuticals, Rexdale, Canada), pH 7.4. VLM homogenates were quickly frozen at 7 70 C. EWAT, IWAT and BAT homogenates were centrifuged (12000 g, for 20 min at 4 C), and the fraction between the upper fat layer and the bottom sediment was removed, diluted with four volumes of the homogenization solution without deoxycholate, and stored at 7 70 C until LPL activity measurement.
Plasma determinations
Serum glucose concentrations were measured with the Beckman glucose analyzer (Beckman Instruments Inc., Fullerton, CA). Insulin was determined by radioimmunoassay (RIA) using a reagent kit from Linco Research (St Charles, MO) with rat insulin as standard (100% crossreactivity with mouse insulin). Serum corticosterone was determined by a competitive protein-binding assay (sensitivity: 0.058 nmolal; interassay coef®cient of variation: 9.0%) using plasma from a dexamethasone-treated female Rhesus monkey as a source of transcortin. 16 Serum TG were measured by an enzymatic method using a reagent kit from Boehringer Mannheim (Montre Âal, Canada) which allowed correction for free glycerol.
Tissue measurements
Frozen liver samples were thawed, and total lipids were extracted according to the method of Folch et al 17 and solubilized in isopropanol. TGs in the lipid extracts were then quantitated using the above-mentioned reagent kit. For the measurement of LPL activity, 100 ml of thawed tissue homogenates were incubated under gentle agitation for 1 h at 28 C with 100 ml of a substrate mixture consisting of 0.2 molal Tris-HCl buffer, pH 8.6, which contained 10 MBqal [carboxyl-
14 C]triolein (Amersham, Oakville, Canada) and 2.52 mmolal cold triolein emulsi®ed in 50 gal gum arabic, as well as 20 gal fatty acid free bovine serum albumin, 10% human serum as a source of apolipoprotein C-II, and either 0.2 or 2 molal NaCl. Free oleate released by LPL was then separated from intact triolein and mixed with Universol (NEN, Montre Âal, Canada) and sample radioactivity was determined in a scintillation counter. LPL activity was calculated by subtracting lipolytic activity determined in a ®nal NaCl concentration of 1 molal (non-LPL activity) from total lipolytic activity measured in a Leptin and lipoprotein lipase F Picard et al ®nal NaCl concentration of 0.1 molal. LPL activity was expressed as microunits (1 mU 1 mmol nonesteri®ed fatty acids released per hour of incubation at 28 C). The interassay coef®cient of variation was 4.8% and was determined using bovine skim milk as a standard source of LPL. Protein content of the tissue extracts was measured by the method of Lowry et al. 18 Data are expressed as speci®c activity of LPL (mUag tissue protein).
Statistical analysis
Data are presented as means AE s.e.m. Group means were compared using a 2 Â 2 factorial analysis of variance (ANOVA) to determine main effects of Genotype (lean and obese), Infusion (PBS and leptin), and their interactions. Differences between individual group means were analyzed by Fisher's protected least squares difference (PLSD) test to evaluate the effects of leptin in lean and obese mice separately. Differences were considered statistically signi®cant at P`0.05. Pearson's correlation coef®-cients were calculated to determine statistical relationships between variables.
Results
At the end of the protocol, PBS-infused obese mice were twofold heavier than their lean counterparts (Table 1) . During the seven-day treatment, cumulative food intake of PBS-infused obese mice was almost twofold higher than that of their lean counterparts (34 g vs 19 g). A week of leptin infusion reduced body weight in obese mice only ( 7 20%, Genotype-Infusion interaction [G Â I]: P 0.0002), and decreased cumulative food intake of obese animals ( 7 77%, G Â I: P`0.0001), whereas the small decrease in that of lean mice was not signi®cant.
As depicted in Table 1 and Figure 1 , there were signi®cant treatment interactions on all plasma variables determined in the fasted state, except glucose levels. Fasted PBS-treated obese mice were hyperglycemic, hyperinsulinemic, and had higher levels of plasma corticosterone and TG compared to their lean counterparts. The liver of the PBS-treated obese animals contained signi®cantly greater amounts of TG (18-fold) than PBS-treated lean mice. Whereas leptin treatment had minimal, non signi®cant effects on plasma glucose and insulin concentrations in lean mice, the infusion led to a complete normalization of glycemia and insulinemia in obese mice. Leptin treatment also decreased plasma corticosterone ( 7 48%) and TG ( 7 23%) levels in obese mice, whereas it had no signi®cant effect in lean animals. Liver TG content was diminished ( 7 28%) by leptin infusion in obese mice only.
In the postprandial state, plasma levels of glucose and TG were higher than in the fasted state, for both lean and obese animals ( Table 1) . Insulinemia in PBSand leptin-treated lean mice was twofold higher in the postprandial, than in the fasted, state (Figure 1 ). In PBS-infused obese mice, postprandial insulinemia 
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F Picard et al was ten-fold higher than in the fasted state, whereas it was only twofold higher in leptin-infused obese mice. The genotype-infusion interactions on plasma variables that were observed in fasted animals were also present and even stronger in the postprandial state. Obese mice had a larger EWAT than lean animals ( Figure 2A , main effect of genotype [G]: P`0.0001). One week of leptin infusion exerted an overall lowering effect on the mass of the depot (main effect of infusion [I]: P 0.006). In absolute terms, leptin treatment was associated with a 70 mg reduction in EWAT mass in lean mice (not statistically signi®cant, NS) and a 300 mg reduction in obese mice (P`0.0001), but the genotype-infusion interaction did not reach statistical signi®cance (P 0.07). LPL speci®c activity of the epididymal depot was close to twofold higher in PBS-treated obese mice than in their lean counterparts and treatment with leptin decreased enzyme activity in obese mice only, to levels that were comparable to those of lean animals (G Â I: P 0.05). As in the case of EWAT, the subcutaneous IWAT of PBS-infused obese mice was heavier and had higher LPL activity than that of lean animals ( Figure 2B , G: P 0.001). Leptin infusion did not reduce the mass of the depot to any signi®cant extent.
However, LPL activity was diminished by leptin in obese mice (G Â I: P 0.03), and the leptin-induced absolute decrease in IWAT LPL activity of obese mice was even greater than that in EWAT.
PBS-infused obese mice had a larger BAT than their lean counterparts ( Figure 3A ). Visual and microscopic examination of the tissue of PBS-infused obese animals indicated that a large proportion of the depot was in fact consisting of white adipocytes (not shown). Leptin treatment caused the depot to revert to its characteristic red-brownish color and decreased its weight in obese mice only (G Â I: P 0.0006). The BAT of the obese groups had the same total amount of protein as those of the lean groups (data not shown) and leptin infusion resulted in a higher relative amount of protein in obese mice only (from 3.5 vs 6.8%, G Â I: P 0.002). LPL activity in BAT was higher in PBS-infused obese animals than in their lean counterparts, and enzyme activity was reduced by leptin in obese mice only, to levels that were comparable to those of lean animals (G Â I: P 0.005). Lean mice had heavier VLM than obese mice ( Figure 3B ). Treatment with leptin had no signi®cant effect on this parameter in either genotype. Whereas genotype did not affect LPL activity in the VLM, leptin infusion 
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produced an overall decrease in enzyme activity (I: P 0.01), this effect being clearly larger in obese than in lean mice.
Analysis of the effects of leptin separately, in the lean and obese cohorts, revealed that leptin infusion did not signi®cantly alter any of the variables in lean mice. Therefore, although genotype-infusion interactions determined by factorial ANOVA did not reach statistical signi®cance in all cases, any main effect of infusion was largely determined by the action of leptin in obese mice.
Discussion
Levels of LPL activity in white adipose tissue (WAT) are closely related to the maintenance of fat-cell size, body weight and obesity. 12 Indeed, genetic and dietinduced obesity are clearly associated with chronic increases in adipose LPL activity in humans and rodents. 19 Inversely, LPL activity is low in storage tissues, when environmental situations favor lipid mobilization, such as physical activity or cold exposure. 13 Therefore, treatments which reduce body fat content should affect adipose LPL in a similar direction. In the present study, leptin infusion reduced white adipose LPL speci®c activity of obese mice, to levels that were indistinguishable from those of lean animals. The large reduction in LPL activity supports the notion that LPL is part of the adaptive mechanisms through which peripheral lipid metabolism adjusted to a new state of energy balance imposed by the presence of leptin, rather than being a passive, linear correlate of the mass of adipose stores. To our knowledge, this is the ®rst report of the consequences of chronic leptin treatment of a leptin-de®cient animal model on tissue-speci®c LPL activity.
Leptin infusion in obese animals led to a reduction in major hormonal modulators of adipose LPL activity. The treatment was associated with a normalization of insulinemia, a ®nding which is consistent with those of other studies. 4, 7 Leptin also normalized postprandial glycemia and insulinemia in fed obese mice, and therefore dampened the large increase in glucose and insulin which occurred postprandially in vehicleinfused obese mice. In addition, plasma corticosterone was reduced by 48% in leptin-treated obese mice. Since insulin and glucocorticoids are two positive modulators of adipose tissue LPL activity, 14, 20, 21 the leptin-induced reduction in plasma concentrations of these two hormones may have mediated the concomitant changes in adipose LPL activity. There is no evidence that leptin directly affects adipose LPL activity through autocrine or paracrine mechanisms, although such a direct action cannot presently be ruled out. Autocrine andaor paracrine effects of leptin on adipocyte lipolysis have indeed been reported recently. 22 Finally, the fact that adipose LPL responded rapidly to a fall in insulinemia also suggests that the enzyme remains sensitive to insulin action in the obaob mouse. The leptin-induced decrease in plasma insulin levels of obese mice was possibly mediated by direct and indirect mechanisms. Messenger RNA for the short- 23 and long-form 24, 25 leptin receptors have been detected in pancreatic beta cells. Leptin has recently been found to inhibit acetylcholine-, but not glucose-induced insulin secretion 26 and to suppress insulin secretion in lean rodents, 27 as well as in pancreatic islets of obaob mice by the activation of ATP-sensitive K channels. 24 Since insulin stimulates leptin expression in white adipocytes, 28 ± 30 it is possible that leptin acts in a closed feedback loop to modulate insulin release when plasma leptin concentrations reach high levels. Leptin was also shown to decrease serum glucose levels in obaob mice pair-fed with lean mice. 31 Notwithstanding such a direct action of leptin on insulin secretion, a strong correlation was observed between food intake and insulinemia in the present study (r 0.81, P 0.0009), suggesting that food intake was a major determinant of insulinemia, and that the effect of leptin on food intake was largely responsible for the decrease in plasma insulin in obese mice. As in the case of insulin, the lowering of corticosterone levels in obese mice was probably the result of indirect (food intake) and direct actions of leptin. The latter indeed exerts a strong attenuating action on the hypothalamic-pituitary-adrenal axis 32 and was shown to directly inhibit cortisol release by bovine adrenocortical cells in primary culture. 33 The leptin-induced decrease in body weight was largely due to a reduction in fat, rather than lean mass, as suggested by the strong relationship between body weight and the sum of the two white adipose depots (r 0.95, P`0.0001) and the lack of effect of leptin on vastus lateralis weight. Comparable observations have been reported in lean and obese mice injected with leptin for 28 d. 7 There is substantial evidence that leptin reduces fat mass not only by reducing food intake, but also by stimulating thermogenesis. Leptin has been shown to increase oxygen consumption and body temperature, 4, 5, 7, 8 as well as noradrenaline turnover 34 and uncoupling protein mRNA levels in BAT of obaob mice. 6 LPL is regarded as part of the mechanism which supplies lipid substrates for thermogenesis, as LPL activity is high in situations of increased BAT thermogenic activity. 35 In the present study, the decrease in BAT LPL activity in leptininfused obese mice may therefore appear paradoxical. However, it is clear that BAT of obese mice was atypical and closer to WAT, as witnessed by its appearance and relative protein content. Accumulation of TG and the appearance of cells with unilocular lipid depots in BAT is typical of genetically obese rodents, especially when thermogenesis is not particularly solicited, such as is the case at 25 C. In the long term, these changes of BAT towards WAT are associated with an increase in LPL activity, probably
Leptin and lipoprotein lipase F Picard et al driven by hyperinsulinemia, since insulin positively modulates BAT LPL as it does in WAT. 36 Therefore, the most likely scenario for the lowering effect of leptin treatment on BAT LPL of obese mice is a reversal of tissue cell morphology towards typical brown adipocytes, with a concomitant lowering of LPL activity due to the disappearance of hyperinsulinemia. Indeed, the higher relative protein content measured in leptin-infused obaob mice suggests that leptin altered the BAT weight of obese mice by reducing its lipid content. The present ®ndings also suggest that any leptin-induced increase in the sympathetic drive to BAT, which would per se tend to stimulate LPL activity, 37 was overwhelmed by the lowering action of decreased insulinemia.
Although still uncertain, insulin appears to directly or indirectly decrease LPL activity in muscle. 20, 38 In the present study, normalization of insulin levels in obese mice by leptin treatment did not lead to an elevation in muscle LPL activity. In fact, leptin treatment rather decreased enzyme activity in the obese cohort. However, central infusion of leptin, which contrary to peripheral administration does affect energy metabolism of lean animals (see below), increased LPL 2±3-fold in the soleus, vastus lateralis and heart of lean Sprague-Dawley rats (F Picard and Y Deshaies, unpublished data). Therefore, the effect of leptin treatment on LPL of muscle tissue itself appears to be stimulatory rather than inhibitory. It can be suggested that skeletal muscle of genetically obese rodents may be in®ltrated with non dissectable lipid depots, although this possibility remains to be veri®ed experimentally. Since LPL speci®c activity is higher in adipose, than in muscle, tissue by approximately 100-fold (compare Figure 3B with Figure 2 ), the consequence of leptin treatment on LPL activity in the VLM of obese mice may have been the result of a reduction in fat in®ltration within the muscle, however small, rather than a lowering action on LPL of muscle tissue itself. Indeed, leptin has been recently shown to induce depletion of adipocytes by apoptosis. 39 In addition to adipose tissue LPL activity, liver TG content and triglyceridemia constituted additional adaptations of lipid metabolism to negative energy balance established in obese mice following leptin treatment. Liver TG content of vehicle-infused obese mice was 18-fold higher than that of control lean animals, a re¯ection of TG overproduction typical of obesity which results from the esteri®cation of NEFA supplied by the large adipose mass and by de novo lipogenesis from dietary precursors. 40 Triglyceride overproduction in obese mice was accompanied by hypertriglyceridemia, consistent with the obesityrelated stimulation of hepatic VLDL secretion. 40 ± 42 Leptin infusion decreased both liver and plasma TG concentrations by approximately 25%, in agreement with the fact that fasting plasma TG levels are largely determined by their rate of secretion by the liver. 43 This relationship is emphasized by the fact that leptin reduced triglyceridemia in obese mice, despite a generalized reduction in tissue LPL activity and a consequent decrease in the global capacity for intravascular TG hydrolysis. The increase in liver insulin sensitivity, the decreased levels of corticosterone and the important changes in energy intake induced by leptin treatment, 40 ± 42 may all have participated in the reduction of liver TG production and secretion, but their relative contribution remains to be quantitated. Along with decreased food intake, a lower TG output by the liver contributed to diminish the delivery of TG destined for storage into WAT.
Subcutaneous leptin infusion in lean animals that already have functional leptin did not result in an additive effect. In fact, although leptin treatment led to some minimal changes in lean mice, neither ®nal body weight, food intake, insulinemia, nor LPL activity were signi®cantly modi®ed. These results are in accordance with those of other studies, 4, 5, 7, 8 but the causes of the relative lack of effect of exogenous leptin in lean animals are still unclear. Although circulating leptin levels have not been measured in the present study, because of a lack of plasma, Trayhurn 44 suggested that such a lack of effect of exogenous leptin may be partly due to a suppression of endogenous leptin production. An alternative possibility is the development of resistance to peripherally, but not centrally, administered leptin in lean animals, 11, 45 perhaps at the level of its transport into the brain. 46 For example, AKR lean mice fed a 10% fat diet were found to be sensitive to peripheral leptin until the day 56 of treatment, after which they were only sensitive to centrally administered leptin. 45 We have also recently observed that central administration of leptin can reduce body weight and WAT LPL in lean Sprague-Dawley rats (F Picard and Y Deshaies, unpublished observations). These ®ndings suggest that lean animals may develop resistance to peripherally administered leptin as their body weight increases, but that they remain highly responsive to leptin delivered directly to the central nervous system.
Conclusion
The consequences of leptin treatment on LPL activity, which were particularly strong in adipose tissues, occurred indirectly, as no direct action of leptin on LPL has yet been demonstrated. As noted above, given the important modulatory action of insulin on adipose LPL, the disappearance of hyperinsulinemia after leptin treatment, via several possible pathways, which undoubtedly include the reduction in food intake, is likely to have mediated the effect of leptin on adipose LPL. The consequences of a reduction in insulinemia on adipose LPL activity may have been strengthened by the concomitant decrease in plasma corticosterone levels. Inasmuch as LPL availability is a limiting factor for the entry of TG-derived fatty acids into adipose stores, the large leptin-induced Leptin and lipoprotein lipase F Picard et al decrease in adipose LPL of obese mice would determine that the rate of lipid deposition in leptin-treated obese mice would not exceed that of lean animals. The present ®ndings indicate that modulation of adipose tissue LPL is part of the adaptive mechanisms to the leptin-induced reduction in lipid¯ux, which limits fat mass accretion in obese obaob mice.
